137-64-4

Usage

Uses

Used in Organic Synthesis:
2-chloro-5-(chlorosulfonyl)-benzoic acid is used as an intermediate in the synthesis of various organic compounds. Its unique chemical structure allows it to be a versatile building block for the creation of a wide range of molecules with different applications in various industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-chloro-5-(chlorosulfonyl)-benzoic acid is used as a key component in the development of new drugs. Its chemical properties make it suitable for the synthesis of various drug candidates, potentially leading to the discovery of novel therapeutic agents.
Used in Chemical Research:
2-chloro-5-(chlorosulfonyl)-benzoic acid is also utilized in chemical research for studying the properties and reactivity of chlorosulfonyl and benzoic acid derivatives. This helps researchers gain a deeper understanding of the underlying chemical mechanisms and potentially develop new synthetic methods or applications.
Used in Dye and Pigment Industry:
In the dye and pigment industry, 2-chloro-5-(chlorosulfonyl)-benzoic acid may be used as a starting material for the production of various dyes and pigments. Its unique chemical structure can contribute to the development of new colorants with improved properties, such as enhanced color strength, stability, and resistance to fading.
Used in Agrochemical Industry:
2-chloro-5-(chlorosulfonyl)-benzoic acid can be employed in the agrochemical industry for the development of new pesticides or herbicides. Its chemical properties may allow for the creation of more effective and targeted agrochemicals, leading to improved crop protection and yield.

InChI:InChI=1/C7H4Cl2O4S/c8-6-2-1-4(14(9,12)13)3-5(6)7(10)11/h1-3H,(H,10,11)

Upstream product

• 118-91-2 ortho-chlorobenzoic acid 

Downstream Products

• 109029-95-0 2-chloro-5-(piperidine-1-sulfonyl)-benzoic acid 
• 380431-72-1 2-chloro-5-(3,4-dihydro-2H-quinoline-1-sulfonyl)-benzoic acid 
• 97-04-1 2-chloro-5-sulfamoyl-benzoic acid 
• 62310-17-2 2-chloro-5-diethylsulfamoyl-benzoic acid 
• 74138-29-7 2-chloro-5-ethylsulfamoyl-benzoic acid 
• 91131-61-2 5-[Bis-(2-hydroxy-ethyl)-sulfamoyl]-2-chloro-benzoic acid 
• 74138-28-6 2-chloro-5-isopropylsulfamoyl-benzoic acid 
• 547739-66-2 2-chloro-5-chlorosulfonyl benzoic acid chloroanhydride 
• 37098-59-2 2-chloro-5-(4-carboxybutylsulfamyl)benzoic acid 
• 24358-29-0 2-chloro-5-(3,5-dimethyl-piperidine-1-sulfonyl)-benzoic acid 
• 632-24-6 2-sulfamoyl-benzoic acid 
• 1422570-74-8 4-chloro-3-(5-(3,5-dichloro-4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)benzene-1-sulfonyl fluoride 
• 21346-66-7 2-chloro-5-(fluorosulfonyl)benzoic acid 
• 1422570-26-0 4-chloro-3-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)benzene-1-sulfonyl fluoride 

Relevant academic research and scientific papers

Nucleophilic Aromatic Substitutions of 2-Halo-5-(sulfamoyl)benzoic Acids and N, O-Bis-alkylation via Phase Transfer Catalysis: Synthesis of RoRγInverse Agonist GSK2981278A

GSK2981278A (1) is a RORγinverse agonist used as a potential topical nonsteroidal therapy for psoriasis. New synthesis of 1 was developed based on a SNAr reaction of (tetrahydro-2H-pyran-4-yl)methanol with an aryl halide intermediate, prepared from 2-halobenzoic acids. The dianion underwent in situ N,O-bis-isobutylation, followed by a reduction to provide 1. The new route eliminated a genotoxic tosylate of (tetrahydro-2H-pyran-4-yl)methanol and a difficult reductive amination from the original synthesis starting from methyl salicylate. A primary version of the route has been scaled up to deliver 125 kg of 1. However, the heating of a strong base in DMSO for an extended period during the bis-alkylation was found to be a safety concern for manufacturing. A safer and greener process was then developed utilizing a facile N,O-bis-alkylation, which was conducted under phase transfer conditions with mild bases such as potassium carbonate and in green solvents such as water. The concise four stage sequence from 2-halobenzoic acids to GSK2981278A (1) had an overall yield of 41%.

Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate

Molecules that bind selectively to a given protein and then undergo a rapid chemoselective reaction to form a covalent conjugate have utility in drug development. Herein a library of 1,3,4-oxadiazoles substituted at the 2 position with an aryl sulfonyl fluoride and at the 5 position with a substituted aryl known to have high affinity for the inner thyroxine binding subsite of transthyretin (TTR) was conceived of by structure-based design principles and was chemically synthesized. When bound in the thyroxine binding site, most of the aryl sulfonyl fluorides react rapidly and chemoselectively with the pK a-perturbed K15 residue, kinetically stabilizing TTR and thus preventing amyloid fibril formation, known to cause polyneuropathy. Conjugation t50s range from 1 to 4 min, ～1400 times faster than the hydrolysis reaction outside the thyroxine binding site. X-ray crystallography confirms the anticipated binding orientation and sheds light on the sulfonyl fluoride activation leading to the sulfonamide linkage to TTR. A few of the aryl sulfonyl fluorides efficiently form conjugates with TTR in plasma. Eleven of the TTR covalent kinetic stabilizers synthesized exhibit fluorescence upon conjugation and therefore could have imaging applications as a consequence of the environment sensitive fluorescence of the chromophore.

TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

PIPERAZINE DERIVATIVES AS GLYT1 INHIBITORS

The invention provides a compound of formula (I) or a salt or solvate thereof: wherein R1, n, X, Y and Z are as defined in the specification, and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.

THERAPEUTIC COMPOUNDS

The present invention provides novel compounds that function as potentiators of glutamate receptors, methods for their preparation, pharmaceutical compositions containing them, and methods of their use in therapy.

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds of formula (I) or pharmaceutically acceptable derivatives thereof, useful in the treatment or prophylaxis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof

A process is provided for the preparation of a compound of formulae (IA) (sidenafil) and (IB) comprising reacting a compound of formula (IIA) and (IIB) respectively in the presence of—OR, wherein R in the case of formation of compound (IA) is CH2CH3and R in the case of formation of compound (IB) is CH2CH2CH3, where X is a leaving group:

Intermediates for preparing hipolipemic agents and method of lowering the blood lipid level in mammals with said agents

Intermediates for preparing benzylthio-, benzylsulfinyl-, and benzylsylfonyl-benzoic acids, and method of lowering the blood lipid level in mammals employing said acids.

Sulfamylbenzoic acids

Certain mono- and disubstituted-5-sulfamylbenzoic acids, many of which are novel, and their use in lowering blood lipid levels in mammals.